Loading...
Madrigal Pharmaceuticals, Inc.
MDGL•NASDAQ
Healthcare
Biotechnology
$298.40
$-0.77(-0.26%)
Madrigal Pharmaceuticals, Inc. (MDGL) Financial Performance & Income Statement Overview
Review Madrigal Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-30.85%
↓ 30.85%
Net Income Growth
-24.69%
↓ 24.69%
Operating Cash Flow Growth
-40.51%
↓ 40.51%
Operating Margin
-133.95%
↓ 133.95%
Gross Margin
96.67%
↑ 96.67%
Net Profit Margin
-123.38%
↓ 123.38%
ROE
-50.54%
↓ 50.54%
ROIC
-51.26%
↓ 51.26%
Madrigal Pharmaceuticals, Inc. (MDGL) Income Statement & Financial Overview
Review Madrigal Pharmaceuticals, Inc.'s (MDGL) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $137.25M | $103.32M | $62.17M | $14.64M |
| Cost of Revenue | $4.51M | $3.01M | $2.15M | $903000.00 |
| Gross Profit | $132.74M | $100.31M | $60.02M | $13.73M |
| Gross Profit Ratio | $0.97 | $0.97 | $0.97 | $0.94 |
| R&D Expenses | $44.17M | $26.08M | $68.74M | $70.82M |
| SG&A Expenses | $167.88M | $141.22M | $107.58M | $105.45M |
| Operating Expenses | $212.05M | $167.31M | $176.33M | $176.27M |
| Total Costs & Expenses | $216.56M | $170.32M | $178.48M | $177.18M |
| Interest Income | $9.37M | $11.08M | $13.02M | $14.22M |
| Interest Expense | $3.30M | $3.50M | $3.68M | $3.66M |
| Depreciation & Amortization | $379000.00 | $363000.00 | $298000.00 | $267000.00 |
| EBITDA | -$69.56M | -$55.55M | -$102.99M | -$148.05M |
| EBITDA Ratio | -$0.51 | -$0.54 | -$1.66 | -$10.11 |
| Operating Income | -$79.31M | -$67.00M | -$116.30M | -$162.54M |
| Operating Income Ratio | -$0.58 | -$0.65 | -$1.87 | -$11.10 |
| Other Income/Expenses (Net) | $6.07M | $7.58M | $9.34M | $10.57M |
| Income Before Tax | -$73.24M | -$59.42M | -$106.96M | -$151.97M |
| Income Before Tax Ratio | -$0.53 | -$0.58 | -$1.72 | -$10.38 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$73.24M | -$59.42M | -$106.96M | -$151.97M |
| Net Income Ratio | -$0.53 | -$0.58 | -$1.72 | -$10.38 |
| EPS | -$3.32 | -$2.50 | -$4.92 | -$7.10 |
| Diluted EPS | -$3.32 | -$2.50 | -$4.92 | -$7.10 |
| Weighted Avg Shares Outstanding | $22.09M | $21.27M | $21.75M | $21.40M |
| Weighted Avg Shares Outstanding (Diluted) | $22.09M | $21.27M | $21.75M | $21.40M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan